Storage
1. The reference standard should be stored at -20°C for optimal stability.
2. All remaining kit components should be stored at 4°C.
The microtiter plate should be kept in a sealed bag with desiccant to minimize exposure to damp air. The test kit will remain stable for six months from the date of purchase provided that the components are stored as described above.
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade
Ciccone, D. N., Kuo, F. S., Boiko, S., Carreiro, S., Kaila, N., McElwee, J. J., Tummino, P. J., & Loh, C.
J Immunother Cancer2025 Jul 30PubMed ID: 40738502Read Article
Applications: ELISA
Reactive species: Mouse
"Abstract: Background: HPK1 (hematopoietic progenitor kinase 1, MAP4K1), an MAP4K serine/threonine kinase family member, is a negative regulator of immune cell function. Genetic HPK1 kinase inactivation or knockout in mice leads to immune cell activation and tumor growth suppression, providing a strong rationale for targeting HPK1 kinase activity as an immuno-oncology therapy.
Methods: A structure-guided drug design approach was used to identify a highly potent and selective small molecule inhibitor of HPK1 kinase activity, NDI-101150. The effect of NDI-101150 in vitro was evaluated on multiple immune cell types and in multiple syngeneic tumor models in vivo.
Results: Treatment with NDI-101150 enhanced T-cell activation in immune-suppressive or exhausted conditions, augmented B-cell activation, and upregulated dendritic cell function, including in settings where anti-programmed cell death protein-1 (PD-1) did not have an effect. These effects translated into significant inhibition of tumor growth in several syngeneic tumor models, including models that are less responsive to anti-PD-1. Importantly, NDI-101150 alone or in combination with anti-PD-1 mediated a highly effective antitumor response on tumor re-challenge, indicating that NDI-101150 induces immune memory against the tumor.
Conclusion: The data presented here indicate that a small molecule kinase inhibitor of HPK1 results in broad immune cell activation, leading to an efficacious antitumor immune response."
Article snippet: At day 14, NDI-101150 treatment not only resulted in a significant enhancement of KLH-IgG (KLH IgG ELISA kit, Creative Diagnostics, Cat. #DEIA3834), more so than anti-PD-1, but also augmented T-independent DNP-IgG, whereas anti-PD-1 had no effect. 
Figure 1. Quantification of KLH-specific IgM and IgG isotypes in blood from mice.
COA
Publication 
Loading ......
